Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): A retrospective study

Autor:	Mehmet Asim Bilen, Nizar M. Tannir, Eric Jonasch, Cihan Duran, Matthew T. Campbell, Emre Altinmakas, Zita Dubauskas Lim
Rok vydání:	2017
Předmět:	Cancer Research medicine.medical_specialty Cabozantinib business.industry Medical record Urology Cancer Retrospective cohort study medicine.disease Surgery Log-rank test chemistry.chemical_compound Oncology chemistry Median follow-up Renal cell carcinoma Medicine business Variant histology
Zdroj:	Journal of Clinical Oncology. 35:478-478
ISSN:	1527-7755 0732-183X
Popis:	478 Background: Cabozantinib (C) prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on first-line VEGFR-TKI. No standard of care systemic therapy exists for the management of patients with metastatic vhRCC. Methods: This is a retrospective, IRB approved study of patients with vhRCC who received C at MD Anderson Cancer Center from January 2014 till June 2016. Information collected from the medical records included the baseline characteristics, toxicity, dose reductions, and OS. A blinded radiologist assessed the radiographic response using RECIST v1.1. Descriptive statistics, the Kaplan Meier method and the log rank test were applied using Microsoft Excel and GraphPad Prism version 6 software. Results: Median PFS was 8.1 months (mos) (95% CI: 5.8-17.8), and median OS was 22.7 mos (95% CI:11-NR), median follow up 13.3 months (95% CI: 9.6-17) . There were no significant differences detected between patients with papillary versus non-papillary histologies with respect to PFS or OS. At last follow-up, 7 patients remain on treatment with median time on therapy for all patients of 17.7 months. There were 2 confirmed PRs (both P) for a 12% ORR, 2 unconfirmed PRs (1 chr, 1 sarc), 10 of 17 (59%) with stable disease, and 5 of 19 with progressive disease (26%), for a disease control rate of 14 of 19 (74%). Of 15 patients who started C at 60 mg/d, 10 (67%) required dose reduction due to toxicity. Multiple patients required treatment breaks but none discontinued therapy due to toxicity. Conclusions: In this retrospective study, cabozantinib produced a clinically meaningful benefit in patients with metastatic vhRCC, the majority of whom had PD on prior VEGFR-TKIs. Prospective trials of cabozantinib in vhRCC are warranted.[Table: see text]
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b7717405a95c5da18d1f5ea23bf777a2 https://doi.org/10.1200/jco.2017.35.6_suppl.478 Zobrazit plný text záznamu